Australia markets closed

Sumitomo Pharma Co., Ltd. (DPM.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
2.4000-0.0400 (-1.61%)
As of 08:00AM CEST. Market open.

Sumitomo Pharma Co., Ltd.

6-8, Doshomachi 2-chome
Chuo-ku
Osaka 541-0045
Japan
81 6 6203 5321
https://www.sumitomo-pharma.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full-time employees6,250

Key executives

NameTitlePayExercisedYear born
Mr. Hiroshi NomuraCEO, President & Representative Director612.34kN/A1957
Mr. Toru Kimura Ph.D.Sr. Mngg Exec. Off. of Glo. Crprate Stgy, F&A, Regen & Cell Med. Off., Kobe Ctr, Mfg. Plt and Dir.N/AN/A1960
Mr. Hiroyuki BabaMngg Exec. Officer of Global Data Design, Lgl Affairs. IP, IT Mgt, & Frontier Bus. Off. & DirectorN/AN/A1959
Mr. Naoki NoguchiExecutive Officer of Corporate Governance & Communications, VP and Head of Corporate CommunicationsN/AN/AN/A
Mr. Takuya TaguchiM.E.O. of Sales & Marketing Div., SVP, Hd of Sales & Marketing Div. and Dep. Hd of Japan Bus. UnitN/AN/AN/A
Ms. Atsuko HiguchiManaging Executive Officer of External Affairs, Corporate Secretariat & Human ResourcesN/AN/AN/A
Mr. Yoshiharu Ikeda Ph.D.Managing Executive Officer of Drug Research Division, Head of Japan Business Unit & DirectorN/AN/A1958
Mr. Koichi KozukiE.O. of R. Aff., Med. Sci., C.R.C. & Q.A., Sr. VP, Hd of C.R.C. & Q.A. Div and Dp. Hd of Japan Bus.N/AN/AN/A
Dr. Shigeyuki Nishinaka Ph.D.Managing Executive Officer of Business Development & Management and DirectorN/AN/A1964
Mr. Isao ShimizuExecutive Officer, Senior VP, Head of Drug Research Division & Senior Executive Research DirectorN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. It has partnerships with Keio University; RIKEN; Kyoto University; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Corporate governance

Sumitomo Pharma Co., Ltd.’s ISS governance QualityScore as of 1 April 2024 is 2. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 3; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.